trending Market Intelligence /marketintelligence/en/news-insights/trending/p4uz8iqMjPJtJU3IOY1UZw2 content esgSubNav
In This List

Shareholders approve Portage Biotech's acquisition of SalvaRx Group unit

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Shareholders approve Portage Biotech's acquisition of SalvaRx Group unit

Shareholders at SalvaRx Group PLC's annual general meeting have approved a sale of the company's stake in its main operating subsidiary SalvaRx Ltd. to Portage Biotech Inc. for $67.5 million.

The shareholders of Toronto-based biotechnology company Portage Biotech also consented to the acquisition of SalvaRx Group's 94.2% stake on Jan. 8, in exchange for 757,943,784 Portage shares.

Shareholders of U.K.-based SalvaRx Group will receive 660,593,556 Portage shares on a proportional basis.

SalvaRx Ltd. is a holding company that develops therapies within the immuno-oncology market through its subsidiary.